Related Experiment Video
Updated: Aug 26, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
346
Cancer cost profiles: The Epicost estimation approach
Silvia Francisci1, Guilia Capodaglio2, Anna Gigli3
1National Centre for Disease Prevention and Health Promotion, National Health Institute, Rome, Italy.
Frontiers in Public Health
|October 10, 2022
Summary
Estimating the economic burden of cancer is crucial for healthcare policy. The Epicost model provides a comprehensive approach to measure cancer care costs using multiple data sources, aiding in policy development.
Area of Science:
- Health Economics
- Oncology
- Public Health Policy
Background:
- Rising cancer burden presents significant challenges to healthcare systems globally.
- Increasing healthcare service utilization drives escalating cancer care costs.
- Accurate measurement and projection of economic burden are vital for effective policy interventions.
Purpose of the Study:
- To introduce and illustrate the Epicost model, a novel comprehensive approach for estimating the economic burden of cancer.
- To detail the methodology for calculating National Health Service reimbursements for cancer diagnosis and treatment costs.
- To demonstrate the model's application using a colon cancer cohort and its adaptability across different healthcare settings.
Main Methods:
- Utilizes a micro-data-driven cost analysis model (Epicost).
- Integrates multiple data sources, including Cancer Registry and administrative healthcare cost data.
- Estimates costs across distinct disease phases: initial, monitoring, and final care.
Main Results:
- The Epicost approach provides a detailed estimation of cancer-related healthcare expenditures.
- Successfully implemented and adapted in Italy and other European countries (Belgium, Norway, Poland).
- Demonstrates replicability in regions with accessible population-based cancer registry and administrative data.
Conclusions:
- The Epicost model offers a robust framework for assessing the economic impact of cancer.
- Facilitates evidence-based policy development for sustainable cancer care management.
- Highlights the importance of data linkage for comprehensive economic burden analysis.
Related Concept Videos
01:21Cancer Survival Analysis
424
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
424
01:24Kaplan-Meier Approach
232
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
232
01:20Actuarial Approach
117
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
117
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162
01:20Comparing the Survival Analysis of Two or More Groups
255
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
255
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K